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Glucagon-like peptide-1 (GLP-1) is a major player in the regulation of glucose homeosta-
sis. It acts on pancreatic beta cells to stimulate insulin secretion and on the brain to inhibit
appetite.Thus, it may be a promising therapeutic agent for the treatment of type 2 diabetes
mellitus and obesity. Despite the physiological and clinical importance of GLP-1, molecular
interaction with the GLP-1 receptor (GLP1R) is not well understood. Particularly, the spe-
cific amino acid residues within the transmembrane helices and extracellular loops of the
receptor that may confer ligand-induced receptor activation have been poorly investigated.
Amino acid sequence comparisons of GLP-1 and GLP1R with their orthologs and paralogs
in vertebrates, combined with biochemical approaches, are useful to determine which
amino acid residues in the peptide and the receptor confer selective ligand-receptor inter-
action. This article reviews how the molecular evolution of GLP-1 and GLP1R contributes
to the selective interaction between this ligand-receptor pair, providing critical clues for the
development of potent agonists for the treatment of diabetes mellitus and obesity.
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INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is an intestinal incretin released
in response to nutrient ingestion that stimulates insulin secre-
tion in a glucose-dependent manner. The insulinotropic effect of
GLP-1 on the pancreas has been demonstrated to be preserved in
animal models of diabetes by stimulating insulin exocytosis (Shen
et al., 1998; Drucker, 2001; MacDonald et al., 2002), and promot-
ing insulin biosynthesis (Fehmann and Habener, 1992; Perfetti
and Merkel, 2000; Moon et al., 2011). Recently, direct effects of
GLP-1 on growth, survival (Xu et al., 1999; Stoffers et al., 2000;
List and Habener, 2004), and differentiation of β-cells have been
reported (Drucker, 2003). Beside its insulinotropic effects, GLP-1
inhibits glucagon (GCG) secretion in pancreatic α-cells (Nauck
et al., 2002), attenuates gastric emptying, and ameliorates glucose
excursion in the gastrointestinal tract (Nauck et al., 2002).
GLP-1 exerts its action through the G protein-coupled recep-
tor (GPCR), GLP1R. This receptor belongs to the class B (or
secretin-like) GPCR family. This GPCR family has only 15 mem-
bers in humans and is characterized by a relatively long N-terminal
extracellular domain (ECD) containing six conserved Cys residues
that form a constraint structure necessary for ligand binding
Abbreviations: Bpa, p-benzoyl-l-phenyl alanine; CRFR, CRF receptor; Cys, cys-
teine; ECD, extracellular domain; ECL, extracellular loop; ER, endoplasmic
reticulum; GCG, glucagon; GCGR, glucagon receptor; GIP, glucose-dependent
insulinotropic polypeptide; GIPR, GIP receptor; GLP-1, glucagon-like peptide-
1; GLP1R, GLP-1 receptor; GPCR, G protein-coupled receptor; PAC1R, PACAP
receptor; PTHR, PTH receptor; TMH, transmembrane helix.
(Couvineau et al., 2004). GLP1R is mainly expressed in pancreatic
β-cells, and upon stimulation by GLP-1, it induces the accumu-
lation of cAMP and the influx of intracellular calcium which
accelerate insulin release from secretory granules (Drucker et al.,
1987; Fehmann et al., 1995).
GLP-1 and GLP1R are also expressed in the central nervous
system. GLP-1 is synthesized largely in the brainstem and trans-
ported along axonal networks to diverse brain regions, including
the hypothalamus (Vrang et al., 2007; Hisadome et al., 2010).
GLP1R is expressed in cerebral cortex, hypothalamus, hippocam-
pus, thalamus, caudate-putamen, and globus pallidum (Alvarez
et al., 2005). In the brain, GLP-1 is known to reduce appetite, lead-
ing to significant reductions in body weight (Zander et al., 2002).
In addition, GLP-1 is likely neuroprotective and involved in neu-
rite growth and spatial learning ability in the brain (During et al.,
2003; Perry et al., 2007).
Due to its combined beneficial effects, GLP-1 has been iden-
tified as a potential therapeutic agent for the treatment of dia-
betes mellitus and obesity. However, the molecular mechanisms
leading to high affinity ligand-receptor binding and receptor acti-
vation have not been fully understood. Studies using alanine
scanning mutagenesis, substitution/modification, and chimeric
peptide construction of GLP-1 have explored the bioactive motifs
of GLP-1(Adelhorst et al., 1994; Gallwitz et al., 1994; Hinke et al.,
2004), yet none have been able to identify the mechanism through
which individual residues in the peptide interact with residues
in the receptor. Recent studies using X-ray crystallography have
demonstrated that residues in the centralα-helical region of GLP-1
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interact with residues in the N-terminal ECD of GLP1R (Runge
et al., 2008; Underwood et al., 2010). However, as ligand-induced
receptor activation is mainly governed by interactions between
residues in the N-terminus of the peptide and residues within the
transmembrane helices (TMH) and extracellular loops (ECL) of
the receptor (Thorens et al., 1993; During et al., 2003), this crystal
structure only accounts for the peptide binding to the ECD of the
receptor. Indeed, virtually no progress has been made in exploring
the receptor binding sites for the N-terminal moiety of the peptide
which is responsible for ligand-induced receptor activation.
Peptide ligands and their receptors have become diversified
through evolutionary processes that ultimately yield families of
related, yet distinct, peptides and receptors (Hoyle, 1999; Cho
et al., 2007; Lee et al., 2009; Kim et al., 2011, 2012). Specific
diversification of peptides, conservation within orthologs but vari-
ation among paralogs, would often confer the selective interaction
with their cognate receptors, allowing discrimination of paralo-
gous receptors (Acharjee et al., 2004; Wang et al., 2004; Li et al.,
2005). Thus, amino acid sequence comparison of the peptide and
receptor with their orthologs and paralogs, along with mutational
mapping approaches, are useful tools helping to determine specific
residues in the peptide ligands and receptors that are essential for
maintaining selective ligand-receptor interaction. Indeed, ligand
binding domains identified in mammalian receptors are highly
conserved in orthologous non-mammalian receptors, indicating
that there is high evolutionary selection pressure to maintain selec-
tivity for their ligands (Acharjee et al., 2004; Wang et al., 2004; Li
et al., 2005). Recently, we reported that evolutionarily conserved
amino acid residues in GLP-1 and core domains of the GLP1R
confer selective ligand-receptor interaction and receptor activation
(Moon et al., 2010, 2012). This article reviews how the molecu-
lar evolution of GLP-1 and GLP1R contributes to acquiring high
affinity interaction between this peptide ligand and receptor.
GENERAL STRUCTURE OF GLP-1 AND ITS FAMILY PEPTIDES
GLP-1 is a product of the GCG gene which encodes a common
GCG-GLP-1-GLP-2 precursor. All three peptides are encoded by
different exons of the GCG gene, raising the possibility of exon
duplications during early vertebrate evolution (Sherwood et al.,
2000). The GCG gene produces one or two mature peptides by a
tissue-specific alternative post-translational process (Kieffer and
Habener, 1999; Irwin, 2001, 2009). For instance, in pancreatic α-
cells mature GCG, but not GLP-1 and GLP-2, is produced. In
intestinal L cells, however, mature GLP-1 and GLP-2, but not
GCG, are generated. One GLP-1 paralog is the glucose-dependent
insulinotropic polypeptide (GIP) which is independently encoded
by the GIP gene (McIntosh et al., 2009). GLP-1 and GIP share a
high degree of amino acid sequence identity, particularly in their
N-terminal moiety, and function similarly by inducing insulin
secretion from β-cells. However, these peptides act through dis-
tinct yet related receptors, GLP1R and GIP receptor (GIPR),
respectively. In addition, albeit absent in mammals, another GLP-
1 paralog is exendin, which was first discovered in Gila monsters
(Heloderma suspectum; Göke et al., 1993). Recently, the full-length
and/or partial cDNAs for exendin were characterized in a few
species, such as Xenopus, chicken, and Gila monster (Irwin and
Prentice, 2011). Although the receptor for exendin has not yet
been identified in non-mammals, exendin exhibits high affin-
ity binding for mammalian GLP1R (Göke et al., 1993). Recent
evidence suggests that the GCG, GIP, and exendin genes were
generated by genome duplication events during early vertebrate
evolution, as these genes are flanked by similar neighboring genes
in the genomes of vertebrates (Irwin, 2002; Irwin and Prentice,
2011).
GLP-1 and its family peptides are 30∼ 40 amino acids in length
and share similarities in amino acid sequence and secondary struc-
ture. All these peptides tend to be disordered in aqueous solutions
but exhibit a marked propensity to form α-helices under mild
ambient conditions, such as in the presence of organic solvents or
lipids (Braun et al., 1983; Gronenborn et al., 1987; Thornton and
Gorenstein, 1994; Inooka et al., 2001; Neidigh et al., 2001; Chang
et al., 2002; Tan et al., 2006; Alana et al., 2007), or upon crystalliza-
tion (Sasaki et al., 1975). It is now well known that the N-terminal
domains of GLP-1-related peptides form a random coil structure,
while the central parts of these peptides have an α-helical struc-
ture. In addition, hydrophobic amino acids at positions 6 and 10,
and a short-chain polar amino acid at position 7 form a helix
N-capping motif through hydrophobic interaction and hydrogen
bonding (Neumann et al., 2008). This capping motif is believed
to introduce a specific local fold that facilitates receptor activation
upon peptide-receptor binding (Neumann et al., 2008).
The N-terminus of GLP-1 and its family peptides share a high
degree of sequence identity (Figure 1). Particularly, Gly4, Thr/Ser5,
Phe6, and Asp/Glu9 are conserved across all GLP-1 paralogs.
Indeed, alanine scanning of these conserved residues of GLP-1
suggest that positions 4, 6, and 9 are crucial for either maintain-
ing secondary structure of the peptide or for interaction with the
receptor (Adelhorst et al., 1994; Gallwitz et al., 1994). His1 and
Thr/Ser7 are common for most GLP-1 paralogs except for GIP,
which has Tyr1 and Ile7 in these positions. Our recent observa-
tion using a chimeric GLP-1/GIP peptide revealed that His/Tyr1
and Thr/Ile7 are responsible for the selective interaction toward
GLP1R and GIPR (Moon et al., 2010). The second position of the
peptides is highly variable across paralogs, even within orthologs
of vertebrates, and it is known to be of lesser importance for recep-
tor binding. This residue can be modified to Ser or another amino
acid to confer protection against cleavage by dipeptidyl peptidase
IV (Hinke et al., 2002). The third position of the peptides is vari-
able across paralogs but conserved within orthologs. Although
the importance of this ortholog-specific third residue in receptor
binding or peptide structure is not fully understood, Glu3 of GIP
is known to be critical for receptor interaction (Hinke et al., 2003;
Gault et al., 2007; Yaqub et al., 2010).
The sequence similarity of the α-helix domain of the peptides is
not pronounced among GLP-1 paralogs, and there are also many
variable residues within orthologs (Figure 1). However, the Phe22,
Ile/Val23, and Leu26 residues that are part of the hydrophobic sur-
face of the α-helix are highly conserved among GLP-1 and its
paralogs. Interestingly, all these residues are known to interact
with highly conserved residues in the ECD of the GLP1R and its
paralogs (Parthier et al., 2007; Runge et al., 2008; Underwood et al.,
2010). Some ortholog-conserved residues, Glu/Asp15 of exendin
and GIP, along with Ala18/19 and Lys20 of GLP-1, are found to
interact with the receptors as was revealed by the peptide-bound
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FIGURE 1 | Amino acid sequence alignment of GLP-1 and its
family peptides. Amino acid sequences of human GLP-1, GLP-2,
glucagon, GIP, and Gila monster exendin are aligned. Residues in red
are conserved sequences within orthologs of vertebrates including
mouse, anole, chicken, Xenopus tropicalis, medaka, fugu, tetraodon,
stickleback, and zebrafish. The residues colored in blue represent
conserved sequences across paralogs. The residues in black are
variable sequences. Underlines indicate the α-helical conformation.
The residues responsible for interaction with their receptor are
shaded.
ECD crystal structures (Parthier et al., 2007; Runge et al., 2008;
Underwood et al., 2010).
GENERAL STRUCTURE OF CLASS B GPCRs
The class B GPCR family is composed of 15 members including
receptors for VIP, PACAP, secretin, GCG, GLP-1, GLP-2, GHRH,
GIP, PTH, calcitonin, calcitonin gene-related peptide, and CRH
(Laburthe et al., 2007). This family shares the general GPCR archi-
tecture: seven TMH interconnected by intracellular loops with
a C-terminal intracellular domain. Class B GPCRs differ from
class A rhodopsin-like GPCRs in the structures of their TMH.
The TMH of class B GPCRs do not contain conserved amino
acid residues such as Asp/Asn2.50 in TMH2, Asn/Asp7.49-Pro7.50-
x-x-Tyr7.53 (N/DPxxY) motif in TMH7, Asp/Glu3.49-Arg3.50-
Tyr/Trp3.51 (D/ERY/W) motif at the junction between TMH3 and
intracellular loop 2 that are commonly found in class A rhodopsin-
like GPCRs (Oh et al., 2005). Instead, class B receptors share a
high degree of amino acid identity in TMH with one another. Fur-
ther, they possess a large and structured N-terminal ECD of ∼120
residues.
Although no experimentally determined full-length class B
receptor structure has been achieved to date, the structure elu-
cidation of individual class B GPCR ECDs represents considerable
progress toward a molecular understanding of their action. The
first structure of the agonist-bound recombinant N-terminal ECD
of the CRH2B receptor has been resolved using NMR (Grace
et al., 2004). Six representative ECD structures of the class B fam-
ily of GPCRs have been determined by X-ray crystallography or
NMR spectroscopy in complex with bound ligand: the human
VPAC1 receptor (Tan et al., 2006), a subtype of human PACAP
receptor (PAC1Rs; Sun et al., 2007), human GIPR (Parthier et al.,
2007), human GLP1R (Runge et al., 2008; Underwood et al., 2010),
human PTH receptor (PTH1R; Pioszak and Xu, 2008), the human
type-1 CRF receptor (CRFR1; Pioszak et al., 2008), and human
GLP2R (Venneti and Hewage, 2011).
Class B GPCRs contain N-terminal signal peptides that are
cleaved off by the signal peptidase of the endoplasmic reticulum
(ER) during the translocation-mediated receptor insertion into
the ER membrane. These signal peptides play a crucial role in
the membrane expression of receptors (Couvineau et al., 2004;
Alken et al., 2005; Huang et al., 2010). After cleavage of the signal
peptide, the N-terminal helix at the beginning of the ECD and
four β-strands forming two antiparallel sheets remain (Figure 2).
Three disulfide bonds formed by a set of six Cys residues lock these
secondary structural elements together. Cysteine residues are com-
pletely conserved across the receptors. The disulfide bond pattern
seems to be conserved in all receptors, suggesting a similar three
dimensional structure. There are three disulfide bonds between the
first and third, the second and fifth, and the fourth and sixth cys-
teine residues (Cys1-Cys3, Cys2-Cys5, Cys4-Cys6). The first bond
(Cys1-Cys3) links the N-terminal α-helix to the first β-sheet. The
second (Cys2-Cys5) connects the two β-sheets, whereas the third
disulfide bond (Cys4-Cys6) holds the C-terminus of the domain
in close proximity to the central β-sheets (Tan et al., 2006; Parthier
et al., 2007, 2009; Sun et al., 2007; Pioszak and Xu, 2008; Pioszak
et al., 2008; Runge et al., 2008; Underwood et al., 2010; Venneti
and Hewage, 2011).
In addition, this core folding is further stabilized by a salt bridge
involving acidic and basic residues flanked by hydrophobic aro-
matic residues. This fold, called the Sushi domain, is conserved
in all class B GPCRs (Grace et al., 2004). Five additional residues,
Asp67, Trp72, Pro86, Gly108, and Trp110 in GLP1R and the corre-
sponding residues in class B GPCRs, are conserved. Particularly,
Asp and the two Trp residues take part in forming the Sushi
domain, suggesting that these residues are crucial for domain sta-
bility and ligand binding. The strongly conserved fold observed in
the ECD of class B GPCRs suggests that a common mechanism
underlies ligand recognition.
The crystal structures of the ligand-bound ECD reveal amino
acid residues that interact with their cognate ligands (Parthier
et al., 2007; Runge et al., 2008; Underwood et al., 2010). It is of
interest to note that many ligand-interacting residues are highly
conserved between GLP1R and its paralogs. For instance, Trp39
in the α1-helix, Asp67 in the β1-sheet, Tyr69 between the β1- and
β2-sheet, Arg121 near TMH1 of GLP1R, residues 87–90 (Tyr-Leu-
Pro-Trp) between the β3- and β4-sheet, Arg101 in the β4-sheet,
and Trp112 near TMH1 of GIPR are all highly conserved across
paralogs (Figure 2). There are also ortholog-specific residues that
interact with the peptide ligands, such as Leu32 in the α1-helix of
GLP1R, and Gly110 and His115 near TMH1 of GIPR.
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FIGURE 2 | Amino acid sequence alignment of GLP1R and its
paralogous receptors. Amino acid sequences of human GLP1R, GLP2R,
GCGR, and GIPR are compared. The signal peptides are indicated in gray.
The residues colored in blue represent conserved sequences across the
GLP-1-related peptide receptors. Residues in red are conserved
sequences within orthologs of vertebrates such as mouse, anole, chicken,
Xenopus tropicalis, medaka, fugu, tetraodon, stickleback, and zebrafish.
The residues in black are variable sequences. The amino acid residues that
interact with their peptides are shaded. The α-helix, β-sheets, and TMH
domains of GLP1R are indicated.
THE TWO-DOMAIN HYPOTHESIS FOR CLASS B GPCR
LIGAND BINDING AND ACTIVATION
Class B GPCRs likely share a similar secondary and tertiary struc-
ture with long N-terminal ECD and highly conserved TMHs. The
orientation and mechanism of interaction of the peptide with
their receptors has been investigated in studies using fragmented
peptide/receptor, and chimeric peptides and receptors (Holtmann
et al., 1995; Stroop et al., 1995; Bergwitz et al., 1996; Laburthe and
Couvineau, 2002; Runge et al., 2003). For instance, the GLP1R
ECD itself is able to bind with its peptide ligands (Graziano et al.,
1996; Van Eyll et al., 1996; Wilmen et al., 1996, 1997; Runge et al.,
2003; Parthier et al., 2007). This binding,however,may not account
for ligand-induced receptor activation (Buggy et al., 1995; Holt-
mann et al., 1995, 1996; Hjorth and Schwartz, 1996; Xiao et al.,
2000). The N-terminally truncated exendin(9–39) is unable to
activate GLP1R even though it binds to the receptor with an
affinity that is comparable to that of wild type exendin (Thorens
et al., 1993). In contrast, exendin(1–9), a short N-terminal frag-
ment of exendin, is able to activate GLP1R although its affinity to
the receptor is quite low (During et al., 2003). Likewise, the GIP
fragment, GIP (7–30), is able to bind to GIPR with high affin-
ity but fails to induce receptor activation. In contrast, GIP (1–14)
exhibits a very low affinity toward the receptor but fully activates
the receptor at a micromolar concentration (Hinke et al., 2001,
2003; Gault et al., 2007). Thus, the two-domain model explain-
ing ligand binding followed by receptor activation has emerged:
the central α-helical and C-terminal portion of the peptide binds
to the N-terminal ECD of the receptor (Al-Sabah and Donnelly,
2003; Dong et al., 2003; Lopez de Maturana et al., 2003) followed
by binding of the N-terminal moiety of the peptide with the core
domain – including the TMH and ECL – of the receptor, confer-
ring receptor activation and G protein coupling (Runge et al., 2003;
Lopez de Maturana et al., 2004; Castro et al., 2005; Wittelsberger
et al., 2006). The two-domain model is generally consistent with
photoaffinity crosslinking studies of several class B receptors. With
a few exceptions, photoreactive side chains in the C-terminus of
the peptide ligand interact with residues in the ECD of the receptor,
whereas photoreactive side chains in the N-terminus of the ligand
bind to the TMH domain (Gensure et al., 2001; Assil-Kishawi and
Abou-Samra, 2002; Dong and Miller, 2002; Dong et al., 2004).
Most recently, strong corroborating evidence for the two-domain
model has been obtained by the structural characterization of the
isolated ECDs of several class B GPCRs (Grace et al., 2004; Parthier
et al., 2007; Sun et al., 2007; Pioszak and Xu, 2008; Pioszak et al.,
2008; Runge et al., 2008; Underwood et al., 2010).
MOLECULAR EVOLUTION OF GLP-1 AND GLP1R FOR THEIR
SELECTIVE INTERACTION
Although GLP-1 and its paralogs share a high degree of sequence
identity and structural similarly, they generally exhibit specific
binding to their own cognate receptors with little cross-reactivity
with paralogous receptors (Runge et al., 2003; Moon et al., 2010,
2012). This observation allows us to presume the presence of dis-
tinct amino acid residues within each peptide and receptor that
allows for the selective interaction with their own partners. Fur-
ther, these facts indicate that evolutionary selection pressure has
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exerted a specific diversification of peptide and receptor: varia-
tion among paralogs but conservation within orthologs. However,
there are some exceptional cross-reactivities among paralogous
partners. For instance, exendin, a GLP-1 paralog in non-mammals,
has a high affinity for the mammalian GLP1R (Göke et al.,
1993). Until now, genetic orthologs for GLP1R have not been
found in teleost fish, yet teleost fish have two copies of GLP-1
peptides which have been generated by teleost-specific genome
duplication (Plisetskaya and Mommsen, 1996; Irwin and Wong,
2005). Interestingly, GLP-1 is able to activate fish GCG receptor
(GCGR) orthologs (Yeung et al., 2002; Irwin and Wong, 2005),
indicating that fish GCGRs have achieved functional response
to GLP-1 through an evolutionary process. These exceptional
cross-reactivities provide a unique opportunity to explore the
identification of specific amino acid residues in the peptides and
receptors responsible for specific ligand-receptor interaction. For
instance, amino acid sequence comparison between GLP-1 and
exendin allows us to predict which amino acid residues are impor-
tant for the activation of GLP1R (Moon et al., 2010). Sequence
comparison between tetrapod GLP1Rs and fish GCGRs has led to
the identification of residues in these receptors that interact with
GLP-1 (Moon et al., 2012).
INTERACTION BETWEEN THE α-HELIX OF THE PEPTIDE AND THE ECD
OF THE RECEPTOR
The crystal structures of the ligand-bound ECD revealed that GLP-
1 is a continuous α-helix from Thr7 to Val27, with a kink around
Gly16. Only the residues between Ala18 and Val27 interact with
the ECD. The α-helical segment of GLP-1 is amphiphilic, allow-
ing hydrophilic and hydrophobic interactions through opposite
faces of the α-helix (Underwood et al., 2010). The hydrophilic
face of GLP-1 comprises residues Gln17, Lys20, Glu21, and Lys28,
of which only Lys20 interacts directly with the ECD by form-
ing a hydrogen bond with the side chain of Glu128. Interestingly,
exendin also possesses a basic residue at position 20 (Arg20), allow-
ing interaction with Glu128 of the GLP1R ECD (Runge et al.,
2008; Underwood et al., 2010). The hydrophobic face of GLP-1
includes Ala18, Ala19, Phe22, Ile23, Leu26, and Val27. The hydropho-
bic residues are exposed toward the complementary hydrophobic
binding pocket in the ECD. Particularly, Phe22, Ile23, and Leu26
of the peptide are found to interact with the highly conserved
residues Val36, Trp39, Asp67, Tyr69, Arg121, and Leu123 in the ECD
of GLP1R (Underwood et al., 2010). The contribution of Phe22,
Ile23, and Leu26 to GLP1R binding has been demonstrated by Ala
substitutions or mutations of these residues (Adelhorst et al., 1994;
Wilmen et al., 1997). It is of interest to note that the GLP-1 family
peptides exendin, GIP, GLP-2, and GCG also contain hydrophobic
residues Phe22, Ile/Va23, and Leu26. Further, residues Trp39, Asp67,
Tyr69, and Arg121 in the GLP1R ECD are also highly conserved in
GLP2R, GIPR, and GCGR (Parthier et al., 2007; Runge et al., 2008;
Underwood et al., 2010; Venneti and Hewage, 2011). This observa-
tion suggests that these residues are evolutionarily conserved and
likely contribute to the primary binding between the α-helix of the
peptides and ECD of the receptors. This may also in part account
for the cross-interaction of oneα-helix of the peptide with the ECD
of other partners (Parthier et al., 2007; Runge et al., 2008; Under-
wood et al., 2010). Indeed, this is supported by the observations
that chimeric peptides containing the GLP-1 N-terminus with
the α-helix of GIP or GCG can induce GLP1R activation with
a relatively high potency (Runge et al., 2003; Moon et al., 2010).
However, the specific interaction of the α-helix of the peptide with
the ECD of its own receptor may be of higher affinity than those
with other related paralogous receptors. For instance, interaction
of Ala19 of GLP-1 with GLP1R-specific Leu32, and Gln19 of GIP
with GIPR-specific Ala32, may explain the higher affinity of each
peptide toward its own receptor than toward paralogous receptors
(Parthier et al., 2007; Underwood et al., 2010).
INTERACTIONS BETWEEN THE N-TERMINUS OF THE PEPTIDE AND THE
CORE DOMAIN OF THE RECEPTOR
Specificity of ligand-receptor binding between a peptide and
the corresponding receptor can be further conferred by bind-
ing between the N-terminus of the peptide and the receptor core
domain. In addition, this interaction allows ligand-induced recep-
tor activation (Thorens et al., 1993; Montrose-Rafizadeh et al.,
1997; Hinke et al., 2001, 2003; During et al., 2003; Gault et al.,
2007). Therefore, many approaches, such as alanine scanning,
photoaffinity labeling, and molecular modeling-based approaches
have explored the specific residues within the peptide and recep-
tor responsible for ligand-receptor interaction (Adelhorst et al.,
1994; Gallwitz et al., 1994; Xiao et al., 2000; Lopez de Maturana
and Donnelly, 2002; Lopez de Maturana et al., 2004; Chen et al.,
2009, 2010; Lin and Wang, 2009). Alanine scanning of GLP1R
demonstrated that residues found between the TMH2 and ECL1
including Lys197, Asp198, Lys202, Met204, Tyr205, Asp215, and Arg227
are likely important for the binding of the receptor to the N-
terminal moiety of GLP-1, as mutations at these residues lead to a
significant decrease in ligand affinity (Xiao et al., 2000; Lopez de
Maturana and Donnelly, 2002; Lopez de Maturana et al., 2004).
However, these observations did not define how these individ-
ual residues interact with in the N-terminal moiety of GLP-1.
Further, Ala mutations in these residues can modify the recep-
tor conformation which may interfere with binding to the ligand.
Recently, using photoaffinity labeling, Chen et al. (2010) observed
that Tyr205 in ECL1 is in close proximity to the p-benzoyl-l-phenyl
alanine (Bpa) at position 6 of GLP-1. However, the mutation of
Tyr205 to Ala in GLP1R does not alter either receptor activity or lig-
and binding, indicating that Tyr205 is not the direct binding site for
the N-terminal moiety of GLP-1. Furthermore, no ligand-bound
crystal structure for the core domain of the class B GPCR family
is currently available. Thus, our understanding of the molecular
mechanism underlying the high affinity interaction between the
N-terminal moiety of the peptide and the receptor core domain is
primitive.
Recently, by comparing the amino acid sequences of GLP-1 and
GLP1R with their orthologs and paralogs in vertebrates, we were
able to obtain clues to help determine which amino acid residues
may be responsible for ligand-receptor interaction (Moon et al.,
2010, 2012). Although the GLP-1-related family of peptides shares
a similarity in the amino acid sequence at the N-terminal moiety,
there are specific, divergent amino acid sequences. For instance,
the N-terminus of GLP-1 and its family peptides starts with either
His1 (for GCG, GLP-1, GLP-2, and exendin) or Tyr1 (for GIP),
and most of the peptides contain Thr at position 7 (GCG, GLP-1,
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and exendin), or Ser (GLP-2); only GIP contains Ile at this posi-
tion. The first and seventh amino acid residues of each peptide are
conserved within orthologs of vertebrate species. Thus, it may be
postulated that His/Tyr1 or Thr/Ile7 residues of GLP-1 and GIP
confer ligand selectivity to their cognate receptors. Indeed, our
recent observation using chimeric GLP-1/GIP peptide reveals that
the His/Tyr1 and Thr/Ile7 residues within these peptides confer dif-
ferential ligand selectivity toward GIPR and GLP1R, respectively
(Moon et al., 2010).
The chimeric GLP1R/GIPR approach together with chimeric
GLP-1/GIP peptides offers a new strategy to determine which
residues in the core domain are responsible for interacting with
His1 and Thr7 of GLP-1 (Moon et al., 2012). For example, this
approach enables us to determine crude motifs in TMH2, ECL1,
and ECL2 of GLP1R which are likely to interact with His1 and
Thr7 of GLP-1. Amino acid sequence comparison of these regions
between those of tetrapod GLP1Rs, fish GCGRs, and vertebrate
GIPRs further define amino acid residues that tentatively interact
with His1 and Thr7 of GLP-1. In this case, we searched for residues
which are conserved within GLP1R ortholog and fish GCGR but
are different from those of GIPRs. We were able to identify Ile196
and Lys197 of TMH2, and Met233 of ECL1, and Asn302 and Met303
of ECL2 in GLP1R (Moon et al., 2012). It is noteworthy that
fish GCGRs exhibit both a significantly high affinity for GLP-1
(Irwin and Wong, 2005) and these conserved residues, even though
other regions are significantly different from tetrapod GLP1Rs
(Figure 3). Mutational mapping together with application of
chimeric GLP-1/GIP peptides reveals that His1-harboring peptides
are sensitive for Asn302 mutations, while Thr7-containing chimeric
peptides are highly sensitive for the Ile196 mutation, indicating a
possible interaction of His1 and Thr7 of GLP-1 with Asn302 and
Ile196 of GLP1R, respectively. Indeed, computer-aided molecular
modeling showed interaction of His1 with Asn302 and of Thr7 with
a binding pocket formed by Ile196, Leu232, and Met233 of GLP1R
(Moon et al., 2012). Interestingly, Asn302 is highly conserved at
the corresponding position in GCGRs (Asn300 for human) and
GLP2Rs (Asn336 for human), and these receptors have peptide
ligands containing His1. In addition, GCGRs that respond to a
Thr7-containing peptide ligands have conserved Val193 and Met231
at the corresponding positions of Ile196, and Met233 of GLP1R,
indicating that these residues may have a contact with Thr7 of
GCG. This possibility, however, needs to be further addressed.
FIGURE 3 | Molecular interaction between GLP-1 and GLP1R.The
amino acid sequences of the N-terminal ECD, TMH2, ECL1, and ECL2 of
vertebrate GLP1Rs, fish GCGRs (which are known to bind GLP-1), and
human GIPR are shown in top and bottom panels. The residues in blue are
conserved between GLP1Rs and GIPR. Residues shown in red are
conserved sequences within the orthologous receptor of vertebrates. The
residues in black are variable sequences. The amino acid residues that
interact with their peptides are shaded. Amino acid sequence alignment of
GLP-1, exendin, and GIP are shown in the middle. Residues which are
identical among three peptides are in green. Residues common for GLP-1
and exendin are in blue. The interaction between peptides and receptors
are indicated by dotted lines.
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CONCLUSION
Although GLP-1 may become a promising therapeutic agent for
the treatment of type 2 diabetes mellitus and obesity, these pep-
tide agonists cannot be administered orally due to their peptide
nature. Thus, orally administered small molecules that regulate
GLP1R need to be developed. However, a bottleneck slowing
the development of these small molecules is the lack of infor-
mation regarding the molecular structure of the ligand-bound
GLP1R. Unfortunately, the crystal structure of the ligand-bound
N-terminal ECD of GLP1R may not fully account for the inter-
action between peptide ligands and receptors. Rather, it is likely
that the seven TMHs and ECLs of the receptors are more critical
than the N-terminal ECD for peptide binding and receptor activa-
tion. Thus, exploring the domains or amino acid residues within
TMHs and ECLs that confer ligand binding and receptor activation
may greatly contribute to the design of the molecular model for
the peptide ligand-receptor complex. In turn, this would facilitate
the development of potent small molecules capable of regulat-
ing GLP1R. Determination of ligand-receptor interaction points
(either by ligand-bound ECD crystal structure or by biochemi-
cal analysis using chimeric peptides and receptors) demonstrates
that conserved residues across paralogous peptides tend to interact
with conserved residues among the paralogous receptors while
the same can be said of conserved residues within orthologous
peptides that likely interact with conserved residues within orthol-
ogous receptors. Thus, evolutionary conservation across ortholog
and specific diversification within paralogs may be required for
maintaining the selective interaction of a peptide ligand with its
cognate receptor. The crystal structure of ligand-bound GLP1R
ECD explains how residues between Ala18 and Val27 interact with
the ECD. Biochemical studies using chimeric peptides and recep-
tors reveal receptor contact points only at His1 and Thr7. Thus, the
residues between the N-terminus through to position 17 of GLP-1
remain to be explored for their impact on binding to the receptor.
Comparative biochemical approaches combined with computer-
aided molecular modeling will discover additional residues in the
peptide and receptor sequences that help understanding the high
affinity binding interaction between the ligand-receptor pair.
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